1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA
Investor Presentation
Reports Second Quarter 2026 Financial Results
Reg. FD, Press Release
CFO Departure - Keith Regnante Resigns; Annita Tanini Appointed Interim CFO
Appoints Anne Prener to its Board of Directors
Keros Therapeutics, Inc. 2026 Annual Meeting Results and Proposals Voted
Announces Participation at Goldman Sachs 47th Annual Global Healthcare Conference
Earnings Release
Q2
Q1
FY 2025
Q3
FY 2023
Registration Statement for Securities to be Offered to Employees
SC TO-I
Tender Offer Statement by Issuer
Registration of Securities
Prospectus filed pursuant to Rule 424(b)(5)
S-3ASR
Definitive Proxy Statement
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Initial Statement of Beneficial Ownership
Amended Schedule 13G - Ownership Report
Amended Tender Offer Statement by Issuer